Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts give Omeros a “Moderate Buy” consensus, based on two buy ratings, one strong-buy rating and three holds. The average 12-month price target is $38, versus a recent share price of $17.19.
• Omeros significantly beat second-quarter expectations, reporting $0.02 in EPS versus an expected $0.27 loss and $28.53 million in revenue versus a $12.69 million estimate. Management cited a strong YARTEMLEA launch, debt reduction and reduced C5 competition.
• Despite positive momentum, analysts have trimmed longer-term EPS forecasts, and director Thomas J. Cable sold 7,500 shares under a pre-arranged trading plan. Institutional investors own 48.79% of the company.

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $38.00.

Several analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research report on Saturday. Weiss Ratings upgraded shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday, April 21st. Finally, Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th.

Insider Transactions at Omeros

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the business's stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director directly owned 35,067 shares in the company, valued at $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming purchased a new stake in Omeros in the 4th quarter worth about $25,000. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros during the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Omeros during the fourth quarter valued at about $33,000. Assetmark Inc. bought a new position in Omeros during the first quarter worth about $38,000. Finally, Tower Research Capital LLC TRC boosted its position in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after purchasing an additional 11,971 shares during the period. Institutional investors own 48.79% of the company's stock.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
• Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
• Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
• Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.

Omeros Price Performance

NASDAQ OMER opened at $17.19 on Friday. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. Omeros has a one year low of $3.94 and a one year high of $18.14. The business's fifty day moving average is $10.89 and its 200-day moving average is $11.54.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. Research analysts expect that Omeros will post -0.94 EPS for the current fiscal year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source